Plozasiran vs RBD5044
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Hypertriglyceridemia
Shared mechanism: APOC3 · full Hypertriglyceridemia pipeline
Plozasiran · Redemplo
Marketed by Arrowhead Pharmaceuticals and partners
NCT06347003 · Phase 3 · completed
This was a randomized, quadruple-masked Phase 3 trial with 446 participants. Its primary endpoint was met according to the sponsor's announcement of 2026-07-22. The result comes from the sponsor's announcement and the sources read give no power calculation, so the grade is moderate.
Next expected readout: July 2028 · NCT06822790 (registry estimate)
Reported efficacy
Percent Change in Fasting Serum Triglyceride (TG) Levels from Baseline to Month 12 Compared to Placebo (Baseline, Month 12): Primary endpoint met: triglyceride reduction vs placebo, and all prespecified secondary endpoints (SHASTA-3, Arrowhead, 2026-07-22). (met)
Result source: NCT06347003
RBD5044
Developed by Suzhou Ribo Life Science and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: March 2027 · NCT07587788 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Hypertriglyceridemia
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
RBD5044: no structured comparison results are available for Hypertriglyceridemia.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Plozasiran
show 65 more results
show 92 more results
show 65 more results
show 65 more results
show 65 more results
show 3 more results
show 3 more results
show 3 more results
show 3 more results
show 3 more results
Available safety results
Plozasiran
| Dropout rate | 7%50 mg NCT04720534 · Phase 2 · registry result, not featured evidence show 6 more results5.5%25 mg NCT04720534 · Phase 2 · registry result, not featured evidence 9.1%10 mg NCT04720534 · Phase 2 · registry result, not featured evidence 7.6%50 mg Q12W NCT04998201 · Phase 2 · registry result, not featured evidence 7.6%50 mg Q24W NCT04998201 · Phase 2 · registry result, not featured evidence 4.5%25 mg Q12W NCT04998201 · Phase 2 · registry result, not featured evidence 10.4%10 mg Q12W NCT04998201 · Phase 2 · registry result, not featured evidence |
|---|---|
| Discontinued due to AEs | 1.8%50 mg NCT04720534 · Phase 2 · registry result, not featured evidence show 6 more results0%25 mg NCT04720534 · Phase 2 · registry result, not featured evidence 1.8%10 mg NCT04720534 · Phase 2 · registry result, not featured evidence 0%50 mg Q12W NCT04998201 · Phase 2 · registry result, not featured evidence 1.5%50 mg Q24W NCT04998201 · Phase 2 · registry result, not featured evidence 0%25 mg Q12W NCT04998201 · Phase 2 · registry result, not featured evidence 1.5%10 mg Q12W NCT04998201 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 12.5%50 mg NCT04720534 · Phase 2 · registry result, not featured evidence show 6 more results3.6%25 mg NCT04720534 · Phase 2 · registry result, not featured evidence 7.4%10 mg NCT04720534 · Phase 2 · registry result, not featured evidence 10.6%50 mg Q12W NCT04998201 · Phase 2 · registry result, not featured evidence 7.6%50 mg Q24W NCT04998201 · Phase 2 · registry result, not featured evidence 7.5%25 mg Q12W NCT04998201 · Phase 2 · registry result, not featured evidence 3%10 mg Q12W NCT04998201 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | 50 mg covid-19 16.1% (placebo 14.8%) upper respiratory tract infection 12.5% (placebo 6.6%) type 2 diabetes mellitus 10.7% (placebo 4.9%) NCT04720534 · Phase 2 · registry result, not featured evidence show 6 more results25 mg covid-19 16.4% (placebo 14.8%) headache 10.9% (placebo 4.9%) sinusitis 7.3% (placebo 0%) NCT04720534 · Phase 2 · registry result, not featured evidence 10 mg covid-19 20.4% (placebo 14.8%) headache 14.8% (placebo 4.9%) urinary tract infection 11.1% (placebo 9.8%) NCT04720534 · Phase 2 · registry result, not featured evidence 50 mg Q12W covid-19 13.6% (placebo 13.8%) type 2 diabetes mellitus 12.1% (placebo 4.6%) urinary tract infection 9.1% (placebo 8%) NCT04998201 · Phase 2 · registry result, not featured evidence 50 mg Q24W type 2 diabetes mellitus 16.7% (placebo 4.6%) upper respiratory tract infection 13.6% (placebo 8%) covid-19 9.1% (placebo 13.8%) NCT04998201 · Phase 2 · registry result, not featured evidence 25 mg Q12W covid-19 16.4% (placebo 13.8%) upper respiratory tract infection 10.4% (placebo 8%) urinary tract infection 9% (placebo 8%) NCT04998201 · Phase 2 · registry result, not featured evidence 10 mg Q12W covid-19 11.9% (placebo 13.8%) type 2 diabetes mellitus 7.5% (placebo 4.6%) bronchitis 6% (placebo 1.1%) NCT04998201 · Phase 2 · registry result, not featured evidence |
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Plozasiran's landscape · RBD5044's landscape